不同生产工艺国产人乳头瘤病毒疫苗不良反应监测分析
2023年11月至2024年6月柳州市疾病预防控制中心开展单中心随机开放平行分组试验,纳入400名9~30岁受试者接种两款国产HPV疫苗。结果显示两剂次组全程及及时接种率显著高于三剂次组,不良反应总发生率18.78%,以接种部位疼痛和发热最常见,9~14岁组不良反应发生率显著低于15~30岁组。
要点
- 两剂次组(9~14岁)全程及全程及时接种率显著高于三剂次组(15~30岁)(P<0.01;χ²=7.06,P<0.01)。
- 不良反应总发生率为18.78%(185/985),最常见为接种部位疼痛4.97%(49/985)和发热4.47%(44/985)。
- 9~14岁组不良反应发生率9.77%(39/399)显著低于15~30岁组24.91%(146/586)(χ²=35.67,P<0.01)。
核心结论
- 两款国产HPV疫苗在9~30岁人群中表现出良好的安全性,不良反应轻微。
- 相较于三剂次接种方案(15~30岁组),两剂次HPV疫苗接种方案(9~14岁组)能显著降低不良反应发生率,提高接种依从性。
研究设计与样本
- 2023年11月至2024年6月柳州市疾病预防控制中心免疫规划所开展单中心、随机、开放、平行分组试验,通过社会招募9~30岁适龄受试者。
- 共纳入400名受试者,随机接种两款国产HPV疫苗(沃泽惠Walrinvax或馨可宁Cecolin),按疫苗说明书分为两剂次组(9~14岁)和三剂次组(15~30岁)。
- 整理接种率信息并监测接种后0~30 d不良反应发生情况。
主要发现
- 两剂次人群全程和全程及时接种率显著高于三剂次组(确切概率计数法,P<0.01;χ²=7.06,P<0.01)。
- 总接种剂次为985剂次,不良反应总发生率为18.78%(185/985),局部反应发生率8.02%(79/985)、全身反应发生率10.76%(106/985)。
- 最常见不良反应为接种部位疼痛4.97%(49/985)和发热4.47%(44/985),未出现4级或特殊关注不良事件。
- 0/6月不同生产工艺的国产HPV疫苗不良反应发生率分别为13.96%(55/394)、17.46%(69/395),差异无统计学意义(χ²=1.83,P>0.05)。
- 9~14岁组与15~30岁组不良反应发生率分别为9.77%(39/399)和24.91%(146/586),差异有统计学意义(χ²=35.67,P<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aims to compare the vaccination rates and incidence of adverse reaction rates following administration of two domestically produced human papillomavirus (HPV) vaccines in individuals aged 9-30 years,investigate the impact of distinct manufacturing processes and vaccination schedules on adverse reaction rates. From November 2023 to June 2024, the Immunization Planning Department of Liuzhou Center for Disease Control and Prevention conducted a single-center, randomized, open-label, parallel-group trial using community-based recruitment of eligible participants aged 9 to 30 years. Participants were randomly assigned to receive either of two domestically produced HPV vaccines (Walrinvax or Cecolin). As specified in the vaccine package inserts, subjects were stratified into a two-dose regimen group (aged 9-14 years) and a three-dose regimen group (aged 15-30 years). Vaccination rates were recorded, and adverse reactions within 0-30 days post-vaccination were monitored. The results showed that a total of 400 participants were enrolled. Both the full vaccination rate and the timely completion rate were significantly higher in the two-dose regimen group compared to the three-dose regimen group (Fisher's exact test, P<0.01; χ²=7.06, P<0.01). A total of 985 doses were administered. The overall adverse reaction rate was 18.78% (185/985), with local and systemic reactions occurring at 8.02% (79/985) and 10.76% (106/985), respectively. The most frequent adverse reactions were injection site pain (4.97%, 49/985) and fever (4.47%, 44/985). No grade 4 or special-interest adverse events were reported.The incidence of adverse reactions for the two domestic HPV vaccines with different production processes (at 0/6 months) was 13.96% (55/394) and 17.46% (69/395) respectively, with no statistically significant difference (χ²=1.83, P>0.05).The adverse reaction rate was significantly lower in the 9-14 years group (9.77%) compared the 15-30 years group (24.91%)(χ2=35.67,P<0.01). In conclusion, both domestic HPV vaccines demonstrated a favorable safety profile in the 9-30 years age group, with mostly mild adverse reactions. Compared to the three-dose schedule (15-30 years group), the two-dose HPV vaccination schedule (9-14 years group) significantly reduced the incidence of adverse reactions and improved vaccination compliance. 本研究比较9~30岁人群接种两款国产人乳头瘤病毒疫苗(HPV)后接种率和不良反应发生率指标,探讨不同生产工艺及不同免疫剂次对接种依从性、不良反应发生率的影响。2023年11月至2024年6月柳州市疾病预防控制中心免疫规划所开展单中心、随机开放、平行分组方式社会招募9~30岁适龄受试者,随机接种两款国产HPV疫苗(沃泽惠Walrinvax或馨可宁Cecolin),根据疫苗接种说明书要求按年龄分为两剂次组(9~14岁)和三剂次组(15~30岁),整理接种率信息并监测接种后0~30 d不良反应发生情况。结果显示,共纳入400名受试者,两剂次人群全程和全程及时接种率显著高于三剂次组(确切概率计数法,P<0.01;χ2=7.06,P<0.01)。总接种剂次为985剂次,不良反应总发生率为18.78%(185/985),其中局部反应发生率为8.02%(79/985)、全身反应发生率为10.76%(106/985),最常见的不良反应为接种部位疼痛(4.97%,49/985)和发热(4.47%,44/985),未出现4级或特殊关注不良事件。0/6月不同生产工艺的国产HPV疫苗在不良反应发生率分别为13.96%(55/394)、17.46(69/395),差异无统计学意义(χ2=1.83, P>0.05)。9~14岁组与15~30 岁组不良反应发生率分别为9.77%(39/399)和24.91%(146/586),差异有统计学意义(χ2=35.67, P<0.01)。综上,两款国产HPV疫苗在9~30岁人群中表现出良好的安全性,不良反应轻微。相较于三剂次接种方案(15~30岁组),两剂次HPV疫苗接种方案(9~14 岁组)能显著降低不良反应发生率,提高接种依从性。.
引用
- Wang HB, Liu Y, Cheng SC, et al. [Adverse reaction surveillance analysis of domestic human papillomavirus vaccines with different production processes]. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 41287334. doi:10.3760/cma.j.cn112150-20250425-00355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。